产品
编 号：F275457
分子式：C42H41FN8O2
分子量：708.83
分子式：C42H41FN8O2
分子量：708.83
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 2170606-74-1
产品详情
生物活性：
DB2313 is a potent transcription factor PU.1 inhibitor with an apoptosis of 14 nM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis of acute myeloid leukemia (AML) cells, and has anticancer effects.
体内研究：
DB2313 (17 mg/kg; i.p.; three times per week; for 3 weeks) treatment decreases leukemia progression and results in increased survival in mice.Animal Model:NSG mice bearing sublethally irradiated (2.0 Gy) and injection with PU.1 URE–/– AML cells
Dosage:17 mg/kg
Administration:Intraperitoneal injection; three times per week; for 3 weeks
Result:Decreased tumor burden and resulted in increased survival.
体外研究：
DB2313 treatment leads to a profound decrease in the growth of PU.1 URE–/– acute myeloid leukemia (AML) cells (IC50 of 7.1 μM), while showing little effect on normal hematopoietic cells at similar concentrations. DB2313 treatment leads to a 3.5-fold increase in apoptotic cells in murine PU.1 URE–/– AML cells. DB2313 also leads to a significant decrease in clonogenicity in the second and third rounds of plating and a complete disruption of clonogenic capacity in the fourth and higher rounds of plating.In AML cells, DB2313 decreases PU.1 occupancy on E2f1, Junb, and Csf1r promoters.
DB2313 is a potent transcription factor PU.1 inhibitor with an apoptosis of 14 nM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis of acute myeloid leukemia (AML) cells, and has anticancer effects.
体内研究：
DB2313 (17 mg/kg; i.p.; three times per week; for 3 weeks) treatment decreases leukemia progression and results in increased survival in mice.Animal Model:NSG mice bearing sublethally irradiated (2.0 Gy) and injection with PU.1 URE–/– AML cells
Dosage:17 mg/kg
Administration:Intraperitoneal injection; three times per week; for 3 weeks
Result:Decreased tumor burden and resulted in increased survival.
体外研究：
DB2313 treatment leads to a profound decrease in the growth of PU.1 URE–/– acute myeloid leukemia (AML) cells (IC50 of 7.1 μM), while showing little effect on normal hematopoietic cells at similar concentrations. DB2313 treatment leads to a 3.5-fold increase in apoptotic cells in murine PU.1 URE–/– AML cells. DB2313 also leads to a significant decrease in clonogenicity in the second and third rounds of plating and a complete disruption of clonogenic capacity in the fourth and higher rounds of plating.In AML cells, DB2313 decreases PU.1 occupancy on E2f1, Junb, and Csf1r promoters.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备